TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05235061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Self-management and Cognitive Training Changes lives in post traumatic epilepsy (HOBSCOTCH-PTE)
Description: HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PTE is an adaptation of the HOBSCOTCH program for people with a traumatic brain injury and post-traumatic epilepsy that incorporates education about TBI, PTE, and cognition into the education module.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home Based Self-management and Cognitive Training Changes lives in post traumatic epilepsy (HOBSCOTCH-PTE)
Description: HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PTE is an adaptation of the HOBSCOTCH program for people with a traumatic brain injury and post-traumatic epilepsy that incorporates education about TBI, PTE, and cognition into the education module.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOBSCOTCH-PTE for Caregivers
Description: Select components of the HOBSCOTCH-PTE program delivered to caregivers consist of session 1 of the HOBSCOTCH-PTE (virtual) program (education module), guidance and instructions on utilizing quick relaxation, and session 8 of the HOBSCOTCH-PTE program (program wrap-up and maintenance planning).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HOBSCOTCH-PTE for Caregivers
Description: Select components of the HOBSCOTCH-PTE program delivered to caregivers consist of session 1 of the HOBSCOTCH-PTE (virtual) program (education module), guidance and instructions on utilizing quick relaxation, and session 8 of the HOBSCOTCH-PTE program (program wrap-up and maintenance planning).
Study: NCT04783415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study: NCT04834895

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mhealth exercise group
Description: Participants were asked to perform 18 exercises specially prepared for neck pain in the M.ü Neck Exercises application according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brochure exercise group
Description: Participants were asked to perform 18 exercises specially prepared for neck pain in the brochure according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
Study: NCT04783415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Given PO
Study: NCT05546099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management of BP medications
Description: Patients will be educated on how to manage their home BP based on a pre-determined protocol. They will then monitor home BP and adjust meds accordingly and under the guidance of the clinical pharmacist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring of home BP
Description: Patients will be educated on how to monitor home BP and will be educated to contact their primary care provider/CKD provider if the BP is above the goal.
Study: NCT05421273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation using passive recharge burst stimulation
Description: Passive recharge burst is marked by a recharge pattern that passively compensates for charge differences.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation using active recharge burst stimulation
Description: Active recharge burst is characterized by negative pulses that directly compensate for charge differences.
Study: NCT06203262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FieldForce™ Ablation System Ventricular Tachycardia
Description: Catheter ablation is a minimally invasive procedure. The physician advances multiple catheters into the heart that are used to diagnose and localize abnormal cardiac tissue involved in the initiation and maintenance of ventricular tachycardia and/or PVCs. Once the abnormal tissue is identified a specialized catheter is advanced to the target and energy is applied to destroy the abnormal tissue. The intervention will be identical to the conventional procedure except that an investigational ablation catheter will be used to deliver energy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FieldForce™ Ablation System Premature Ventricular Contractions
Description: Catheter ablation is a minimally invasive procedure. The physician advances multiple catheters into the heart that are used to diagnose and localize abnormal cardiac tissue involved in the initiation and maintenance of ventricular tachycardia and/or PVCs. Once the abnormal tissue is identified a specialized catheter is advanced to the target and energy is applied to destroy the abnormal tissue. The intervention will be identical to the conventional procedure except that an investigational ablation catheter will be used to deliver energy.
Study: NCT06044948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lenses
Description: Daily disposable, silicone hydrogel spherical contact lenses
Study: NCT06519370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA018-ADC
Description: Subjects will receive FDA018-ADC 10 mg/kg of body weight via intravenous(IV) infusion on Day1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: 1.4mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 800 to 1200 mg/m\^2 will be administered IV on day 1 and Day 8 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: 25 mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle
Study: NCT05586217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INCENTIVE SPIROMETRY
Description: * Sit up and hold the device.~* Then Place the mouthpiece spirometer in mouth and make a good seal over the mouthpiece with lips.~* Breathe out (exhale) normally.~* Breathe in (inhale) slowly. A piece in the incentive spirometer will rise as you breathe in. And try to get this piece to rise as high as you can.~* Usually, there is a marker placed by your doctor that tells you how big of a breath you should take.~A smaller piece in the spirometer looks like a ball or disk.~* Your goal should be to make sure this ball stays in the middle of the chamber while you breathe in.~* If you breathe in too fast, the ball will shoot to the top.~* If you breathe in too slowly, the ball will stay at the bottom. Hold your breath for 3 to 5 seconds. Then slowly exhale.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active cycle of breathing
Description: Breathe in and out gently through your nose if you can. If you cannot, breathe through your mouth instead. If you breathe out through your mouth, it's best to use breathing control with 'pursed lips breathing'. keep your shoulders relaxed.~Try closing your eyes to help you to focus on your breathing and to relax. Breathing control should continue until the person feels ready to progress to the other stages in the cycle. Try to keep your chest and shoulders relaxed.~At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing out. Breathe out gently and relaxed. Repeat 3 - 5 times. Sit up straight with chin tilted slightly up and mouth open.~Take a slow deep breath to fill lungs about three quarters full. Hold breath for two or three seconds. Exhale forcefully, but slowly, in a continuous exhalation to move mucus from the smaller to the larger airways

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing
Description: Breathe in and out gently through your nose if you can. If you cannot, breathe through your mouth instead. If you breathe out through your mouth, it's best to use breathing control with 'pursed lips breathing'. keep your shoulders relaxed.~Try closing your eyes to help you to focus on your breathing and to relax. Breathing control should continue until the person feels ready to progress to the other stages in the cycle. Try to keep your chest and shoulders relaxed.~At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing out. Breathe out gently and relaxed. Repeat 3 - 5 times. Sit up straight with chin tilted slightly up and mouth open.~Take a slow deep breath to fill lungs about three quarters full. Hold breath for two or three seconds. Exhale forcefully, but slowly, in a continuous exhalation to move mucus from the smaller to the larger airways
Study: NCT06217731

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Laser+clonazepam
Description: treated with the Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month and Rivotril 0.25mg once every 24 hours for a month

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Laser Sham
Description: INACTIVE Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Active Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month
Study: NCT04718103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3511294
Description: GSK3511294 was administered using a pre-filled syringe.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered as normal saline using a pre-filled syringe.
Study: NCT06217731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: Rivotril 0.25mg once every 24 hours for a month
Study: NCT04798820

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary education(nutritional counselling)
Description: Dietary education provided to gastrectomy patients by dietitian.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary education(nutritional counselling)
Description: Dietary education provided to gastrectomy patients by dietitian.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary education(nutritional counselling)
Description: Dietary education provided to gastrectomy patients by dietitian.
Study: NCT06424327

Intervention type: OTHER
Intervention: Patient-Reported Outcomes Measurement Information System
Description: Participants-reported outcomes will be collected using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS is a web-based platform developed by the National Institutes of Health. Scoring is standardized on a scale from 0 to 100, with a population mean of 50 and standard deviation of 10 units. High scores mean more of the concept being measured. This study will use PROMIS surveys assessing three domains: physical function (PROMIS bank version 2.0), pain interference (PROMIS bank version 1.1), and dyspnea severity (PROMIS bank version 1.0)
Study: NCT05450302

Intervention type: OTHER
Intervention: PURE EP (Observational Study)
Description: This is an observational study. No interventions involved in this study.
Study: NCT06474962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pause
Description: 7 days of no e-cigarette consumption
Study: NCT05823441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Volunteers inhale 24 units of oxytocin spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin nasal spray
Description: Volunteers inhale 24 units of oxytocin spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers inhale 24 units of placebo spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers inhale 24 units of placebo spray

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stranger
Description: Volunteers watch a video of a pain test and attach a photo of a stranger

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stranger
Description: Volunteers watch a video of a pain test and attach a photo of a stranger

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acquaintance
Description: Volunteers watch a video of a pain test and attach a photo of an acquaintance

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acquaintance
Description: Volunteers watch a video of a pain test and attach a photo of an acquaintance
Study: NCT06253546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-44749
Description: Pharmaceutical form:~extended-release injectable suspension~Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-44749
Description: Pharmaceutical form:~extended-release injectable suspension~Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-44749
Description: Pharmaceutical form:~extended-release injectable suspension~Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Olanzapine
Description: Pharmaceutical form:~tablet~Route of administration:~oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Olanzapine
Description: Pharmaceutical form:~tablet~Route of administration:~oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Olanzapine
Description: Pharmaceutical form:~tablet~Route of administration:~oral
Study: NCT04795622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultherapy treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: OTHER
Intervention: Untreated-control / delayed-treatment
Description: Untreated-control, followed by Ultherapy treatment (focused ultrasound energy delivered below the surface of the skin)
Study: NCT05501912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABM-1310
Description: Dose escalation starting dose will be based on a priming dose one level below the highest safe dose or two levels below the MTD that has been tested in US clinical trials.~Dose expansion will be initiated at the MTD or the optimal dose determined by the SMC as a fixed dose level.
Study: NCT06511882

Intervention type: DRUG
Group type: OTHER
Intervention: Azacitidine
Description: Standard of Care Intravenous (IV) infusion
Study: NCT05423080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus injection of remimazolam
Description: Participants in this group are administered 0.2 mg/kg remimazolam via the bolus injection method for 20 seconds during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will administer additional doses of 0.05 mg/kg repeatedly until LOC occurs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of remimazolam
Description: Participants in this group are administered remimazolam at a rate of 6 mg/kg/hr via the continuous infusion method during anesthesia induction. If loss of consciousness (LOC) does not occur, the investigators will escalate infusion dose to 12 mg/kg/hr until LOC occurs.
Study: NCT06511882

Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: Standard of Care Intravenous (IV) infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Venetoclax
Description: Standard of Care PO (By Mouth)
Study: NCT05996653

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Saturation Transfer (ST)-MRI
Description: Non-contrast magnetic resonance imaging Saturation Transfer scans consisting of magnetization transfer (MT) and chemical exchange saturation transfer (CEST)
Study: NCT03497793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNUBY
Description: Following written informed consent, mother will be issued with an appropriate sized SNUBY® for her use only. The infant will be placed in skin-to-skin in SNUBY®, infant chest to mother's chest whilst the mother is seated on a reclining chair, allowing the infant to be further stabilised by gravity. Monitor wires, IV lines and/or ventilation tube will be secured using the ties on the SNUBY®. The infant's temperature, pulse and SaO2 will be recorded prior to skin-to-skin, repeated as required for the infant's clinical condition or at 30min intervals for the duration of skin-to-skin. Maternal and infant behaviour will be recorded, including spontaneous breastfeeding. The time taken to put the infant into skin-to-skin care, time in skin-to-skin care and time to return to cot will be recorded.
Study: NCT04802070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CIK
Description: Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory (4 dose levels)
Study: NCT05437211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual-reality (VR) Based Solution
Description: VR-based solution comprises a mobile phone application including explanation on the different steps to be followed to perform infusions in satisfactory conditions, notably as regards safety, as well as VAS for pain and anxiety to be completed at each Factor VIII or Factor IX infusion between inclusion and the Week 4 visit. It also comprises a 3D mask (to be used before or during infusions) including simulation of the infusions themselves (before infusion) and a relaxing and distracting content (during and after infusions).
Study: NCT06550271

Intervention type: DRUG
Intervention: Rapamycin
Description: Rapamycin in 2 different dosage forms (compounded and generic)

Intervention type: DRUG
Intervention: Rapamycin
Description: Rapamycin in 2 different dosage forms (compounded and generic)
Study: NCT05869565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% infusion alone or in combination with Sodim acetate with normal saline in a ratio 1;1, 2;1 and 3;1
Description: Patients will be enrolled in the study and randomized into one of four arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% infusion alone or in combination with Sodim acetate with normal saline in a ratio 1;1, 2;1 and 3;1
Description: Patients will be enrolled in the study and randomized into one of four arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% infusion alone or in combination with Sodim acetate with normal saline in a ratio 1;1, 2;1 and 3;1
Description: Patients will be enrolled in the study and randomized into one of four arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% infusion alone or in combination with Sodim acetate with normal saline in a ratio 1;1, 2;1 and 3;1
Description: Patients will be enrolled in the study and randomized into one of four arms
Study: NCT02642523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Subjects will receive an intravenous infusion of recombinant human b-type natriuretic peptide (BNP) (Nesiritide) over 2 hours at 2 doses: 0.003 ug/kg/min for 1 hour, followed by 0.01 ug/kg/min for 1 hour. Nesiritide (Johnson and Johnson) is FDA-approved for the treatment of heart failure. Study investigators received approval from the FDA for an IND exemption for nesiritide in this study. While receiving the BNP infusion, subjects will also receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: The hyperinsulinemic-euglycemic insulin clamp, which will last between 2-2.5 hours, involves continuous intravenous infusions of human regular insulin and of dextrose solution. Simultaneously, subjects receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects will receive an intravenous infusion of normal (0.9%) saline over 2 hours at a rate of 0.25 ml/kg/min. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
Study: NCT03548233

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: bcg vaccine
Description: live attenuated vaccine
Study: NCT06461845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration with conventional therapy
Description: This group will be given WBV training session, by using a WBV platform was conducted to the study group. The wBV program comprises various positions such as the child stands in an erect position, sitting, and in kneeling position on vibrating platform. This platform vibrates horizontally at a frequency ranged from 10 to 25 Hz. The participants had to carry out each position for 2 min in the first month, and then it was increased to 3 min in the second month. The rest period between each position was 1 min in the first month, then it became half a minute in the second month. The duration of the vibration exposure was 10 min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: This group will be provided with the conventional physical therapy. To this, stretching activities to keep up muscle elasticity particularly Achilles tendon, hamstring muscles, hip flexors and adductors; strength training to hip flexor, knee extensor, and ankle dorsiflexor;

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: This group will be provided with the conventional physical therapy. To this, stretching activities to keep up muscle elasticity particularly Achilles tendon, hamstring muscles, hip flexors and adductors; strength training to hip flexor, knee extensor, and ankle dorsiflexor;
Study: NCT04883788

Intervention type: OTHER
Intervention: Pandemic period
Description: Perioperative care (nursing and physiotherapy) provided to patients treated with hip and knee replacement during the pandemic period
Study: NCT05768789

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Buoy Electrolyte
Description: Buoy intervention amount is 4% of total body weight given in 16 divided doses over 4 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nuun
Description: Nuun intervention given as 1L bolus and then free water in divided doses for a total of 4% total body weight.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water serves as a control